# Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy With Tenofovir in ACLF-HBV

> **NCT04431375** · NA · UNKNOWN · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 70 (estimated)

## Conditions studied

- Acute-On-Chronic Liver Failure
- Hepatitis B

## Interventions

- **BIOLOGICAL:** Plasma Exchange
- **DRUG:** Tenofovir
- **OTHER:** Fecal Mircobiota Transplantation

## Key facts

- **NCT ID:** NCT04431375
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-22
- **Primary completion:** 2022-06-10
- **Final completion:** 2022-06-10
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2022-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04431375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04431375, "Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy With Tenofovir in ACLF-HBV". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04431375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*